en · de · es · fr · pt
melanotan-2-notes.peptides6579.com › News › Identity And Chemical Background — Field Notes

Identity And Chemical Background — Field Notes

By Editorial Desk · published 2025-10-07 · last reviewed 2025-11-02 · News

This is a working overview of afamelanotide, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-11-02. Anything still debated is marked as such rather than presented as settled.

Identity and Chemical Background

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Regulation, Literature and Verification

Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.

Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Free base; salt forms differ
Molecular weightApproximately 1024 g/molCalculated for the free base
AppearanceWhite to off-white powderTypically supplied as a lyophilised solid
SolubilitySoluble in water and polar solventsPoorly soluble in non-polar solvents
Typical storage-20 degrees Celsius, dry, protected from lightRefers to the solid form

Melanotan II Background and Mechanism

Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.

Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.

Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.

Related pages on this site

Storage, Stability, and Analysis

Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.

Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.

Notes from published material

Purified animal-sourced insulin was initially the only type of insulin available for experiments and diabetics. John Jacob Abel was the first to produce the crystallised form in 1926. Evidence of the protein nature was first given by Michael Somogyi, Edward A. Doisy, and Philip A. Shaffer in 1924. It was fully proven when Hans Jensen and Earl A. Evans Jr. isolated the amino acids phenylalanine and proline in 1935. The amino acid structure of insulin was first characterized in 1951 by Frederick Sanger, and the first synthetic insulin was produced simultaneously in the labs of Panayotis Katsoyannis at the University of Pittsburgh and Helmut Zahn at RWTH Aachen University in the mid-1960s. Synthetic crystalline bovine insulin was achieved by Chinese researchers in 1965. The complete 3-dimensional structure of insulin was determined by X-ray crystallography in Dorothy Hodgkin's laboratory in 1969. Hans E. Weber discovered preproinsulin while working as a research fellow at the University of California Los Angeles in 1974. In 1973–1974, Weber learned the techniques of how to isolate, purify, and translate messenger RNA. To further investigate insulin, he obtained pancreatic tissues from a slaughterhouse in Los Angeles and then later from animal stock at UCLA. He isolated and purified total messenger RNA from pancreatic islet cells which was then translated in oocytes from Xenopus laevis and precipitated using anti-insulin antibodies.

Inhaling heroin appears to rarely lead to toxic leukoencephalopathy. There are also documented cases of both severe acute asthma and exacerbation of underlying asthma caused by heroin inhalation, potentially resulting in death.

In genetics, attenuation is a regulatory mechanism for some bacterial operons that results in premature termination of transcription. The canonical example of attenuation used in many introductory genetics textbooks, is ribosome-mediated attenuation of the trp operon. Ribosome-mediated attenuation of the trp operon relies on the fact that, in bacteria, transcription and translation proceed simultaneously. Attenuation involves a provisional stop signal (attenuator), located in the DNA segment that corresponds to the leader sequence of mRNA. During attenuation, the ribosome becomes stalled (delayed) in the attenuator region in the mRNA leader. Depending on the metabolic conditions, the attenuator either stops transcription at that point or allows read-through to the structural gene part of the mRNA and synthesis of the appropriate protein. Attenuation is a regulatory feature found throughout Archaea and Bacteria causing premature termination of transcription. Attenuators are 5'-cis acting regulatory regions which fold into one of two alternative RNA structures which determine the success of transcription. The folding is modulated by a sensing mechanism producing either a Rho-independent terminator, resulting in interrupted transcription and a non-functional RNA product; or an anti-terminator structure, resulting in a functional RNA transcript. There are now many equivalent examples where the translation, not transcription, is terminated by sequestering the Shine-Dalgarno sequence (ribosomal binding site) in a hairpin-loop structure.

Animals ingest amino acids in the form of protein. The protein is broken down into its constituent amino acids in the process of digestion. The amino acids are then used to synthesize new proteins and other nitrogenous biomolecules, or they are further catabolized through oxidation to provide a source of energy. The oxidation pathway starts with the removal of the amino group by a transaminase; the amino group is then fed into the urea cycle. The other product of transamidation is a keto acid that enters the citric acid cycle. Glucogenic amino acids can also be converted into glucose, through gluconeogenesis. Of the 20 standard amino acids, nine (His, Ile, Leu, Lys, Met, Phe, Thr, Trp and Val) are called essential amino acids because the human body cannot synthesize them from other compounds at the level needed for normal growth, so they must be obtained from food.

Sources: en.wikipedia.org

Further detail

== Veterinary use == Remifentanil has a very short half-life and quick onset with recovery occurring in a few minutes regardless of length and dosage provided. Remifentanil is more effective in dogs than cats, although an increase in the dosage in cats can achieve equivalent analgesia and anti-nociception. The half-life is 6 minutes in the dog. This half-life does not increase with increased dosage or prolonged usage and thus remifentanil recovery is very quick. Hyperalgesia and tolerance has been demonstrated in rodents and rabbits but not dogs and cats. In equines remifentanil can provide long-lasting sedation when combined with xylazine and used as constant rate infusion.

Gas phase regioselectivity is calculated to favor 1,5 addition over 1,4 addition by up to 2.9 kcal/mol in activation energy in the gas phase; solvation corrections give the same energy barriers for both regioisomers, explaining the regioisomeric mix that results from DIFO cycloadditions. While the 1,4 isomer is disfavored by its larger dipole moment (all electron-rich substituents on one side), solvation stabilizes it more strongly than the 1,5 isomer, eroding regioselectivity. Experimental studies by Carolyn R. Bertozzi report a nearly 1:1 ratio of regioisomers, confirming the predicted lack of regioselectivity in the addition. Furthermore, nearly all of the distortion energy (92%) arises from the distortion of the 1,3 dipole rather than the cyclooctyne, which has a pre-distorted ground state geometry that increases its reactivity. Fluorination decreases the distortion energy by allowing the transition state to be achieved with a lesser distortion of the 1,3-dipole during a reaction, resulting in a larger dipole angle.

Chiang's general He Yingqin then proposed building a highway from Kangding to Xining through Yushu, but Liu once again blocked Nationalist attempts to introduce its soldiers in Xikang. Kim Hee-shin argues that Liu, in his dealings with various political factions, was mainly driven by political survival, with ideology playing little to no role in his considerations. This meant that although Xikang cooperated with the central government, he maintained ties with anti-Chiang factions and refused to let Nationalist garrisons into his province. An attempt by the Nationalist official H. H. Kung to more closely oversee Xikang's affairs in 1939 ended in failure after the representative he sent, Peter Goullart, was placed under house arrest by Liu's forces. To prevent the CC Clique from taking control of his province, Liu used his position as head of the provincial government to block their influence.

=== Locating trials === Depending on the kind of participants required, sponsors of clinical trials, or contract research organizations working on their behalf, try to find sites with qualified personnel as well as access to people who could participate in the trial. Working with those sites, they may use various recruitment strategies, including patient databases, newspaper and radio advertisements, flyers, posters in places the patients might go (such as doctor's offices), and personal recruitment of trial participants by investigators. Volunteers may search directly to locate trials using a registry run by the U.S. National Institutes of Health and National Library of Medicine to identify studies that are currently recruiting participants, offering simplified navigation and real-time enrollment trial information. Software exists to enable clinicians to find trial options for a possible participant based on genomic data for people with cancer.

7.46 mg dihydrocodeine as co-dydramol 7.46/500 (e.g. in the branded product Paramol). 10 mg dihydrocodeine as co-dydramol 10/500, this is also the preparation to be dispensed if no strength is specified on a prescription. 20 mg dihydrocodeine as co-dydramol 20/500 (e.g. branded products Paracod 500/20 and Remedeine). 30 mg dihydrocodeine as co-dydramol 30/500 (e.g. branded products Paracod 500/30 and Remedeine Forte).

Sources: en.wikipedia.org

Supporting material

Carindacillin (INN), also known as carbenicillin indanyl (USAN), is a penicillin antibiotic. It is a prodrug of carbenicillin. It is administered orally, as the sodium salt. It was formerly marketed in the United States by Pfizer under the brand name Geocillin. Pfizer withdrew Carindacillin from the U.S. market sometime after 2008.

=== Endocrine disruption === LeBlanc's research in the field of toxicology, particularly centered on endocrine disruption, has contributed to the understanding of the impact of environmental contaminants on human and wildlife health. He investigated the impacts of endocrine-disrupting chemicals on mammals, fishes, reptiles, and invertebrates. He identified the suite of nuclear receptors in the crustacean, Daphnia pulex, and functionally characterized several of these receptors. He deciphered the neuro-endocrine signaling pathway responsible for sex determination in some crustaceans, including the discovery of the hormone responsible for sex determination, methyl farnesoate, and its receptor protein. He also demonstrated that some insecticides can mimic the action of methyl farnesoate in daphnids resulting in altered sex ratios of offspring. In 2005, LeBlanc created a mathematical model that integrated concentration addition, response addition, and toxicokinetic interactions to enable the assessment of the toxicity of chemical mixtures. He demonstrated the utility of this model by assessing the joint toxicity of 9 chemicals commonly found in surface waters in the US. This model has been used by regulatory agencies and has been recommended by the National Research Council in the assessment of risks to endangered and threatened species from exposure to pesticide mixtures.

=== Initial lesion === Unlike most regions of the body, the oral cavity is perpetually populated by pathogenic microorganisms; because there is a constant challenge to the mucosa in the form of these microorganisms and their harmful products, it is difficult to truly characterize the boundary between health and disease activity in the periodontal tissues. The oral cavity contains over 500 different microorganisms. It is very hard to distinguish exactly which periodontal pathogen is causing the breakdown of tissues and bone. As such, the initial lesion is said to merely reflect "enhanced levels of activity" of host response mechanisms "normally operative within the gingival tissues." Healthy gingiva are characterized by small numbers of leukocytes migrating towards the gingival sulcus and residing in the junctional epithelium. Sparse lymphocytes, and plasma cells in particular, may exist just after exiting small blood vessels deep within the underlying connective tissue of the soft tissue between teeth. There is, however, no tissue damage, and the presence of such cells is not considered to be an indication of a pathologic change. When looking at the gums they look knife like and a very light pink or coral pink. On the contrary, the initial lesion shows increased capillary permeability with "very large numbers" of neutrophils migrating from the dilated gingival plexus into the junctional epithelium and underlying connective tissue (yet remaining within the confines of the region of the sulcus) and macrophages and lymphocytes may also appear.

Past hypersensitivity or allergy to lorazepam, its ingredients in tablets or injections or any other benzodiazepine. Ataxia, a neurological clinical sign, consisting of unsteady and clumsy motion of the limbs and torso, due to the failure of gross muscle movement coordination, most evident on standing and walking. It is the classic way in which acute alcohol intoxication may affect a person. Benzodiazepines are not recommended to be administered to people who are already ataxic. Lorazepam has pupil-dilating effects, which may further interfere with the drainage of aqueous humor from the anterior chamber of the eye, thus worsening narrow-angle glaucoma. Sleep apnea may be worsened by lorazepam's central nervous system depressant effects. It may further reduce the person's ability to protect their airway during sleep. Myasthenia gravis, which is characterized by muscle weakness, may have exacerbated symptoms with muscle relaxants such as lorazepam. Lorazepam belongs to the Food and Drug Administration (FDA) pregnancy category D, which means it is likely to cause harm to the developing baby if taken during the first trimester of pregnancy. The evidence is inconclusive as to whether lorazepam if taken early in pregnancy results in reduced intelligence, neurodevelopmental problems, physical malformations in cardiac or facial structure, or other malformations in some newborns. Lorazepam given to pregnant women antenatally may cause floppy infant syndrome in the neonate, or respiratory depression necessitating ventilation.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan-2 a naturally occurring substance?

No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.

How is melanotan-2 distinguished from afamelanotide?

Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.

Why does the compound appear in tanning-related discussion?

Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.

Has it been tested in clinical trials?

Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.

Network